Inclusion Criteria

last updated: 04/2019

print a list

Kinase-/ JAK -Inhibitoren
Olumiant® (Baricitinib)
Rinvoq® (Upadacitinib)
Xeljanz® (Tofacitinib)

Biologika
Cimzia® (Certolizumab Pegol)
Enbrel® (Etanercept)
Kevzara® ( Sarilumab )
Orencia® (Abatacept)
Simponi® (Golimumab )

Biosimilar
Amgevita® (Adalimumab)
Benepali® (Etanercept)
Erelzi® (Etanercept)
Flixabi® (Infliximab)
Hulio® (Adalimumab)
Hyrimoz® (Adalimumab)
Idacio® (Adalimumab)
Imraldi® (Adalimumab)
Nepexto® (Etanercept)
Remsima® (Infliximab)
Rixathon® (Rituximab)
Ruxience® (Rituximab)
Zessly® (Infliximab)

Kontrollgruppe
Alle zugelassenen csDMARDs